LAUSR

349 CONSOLIDATION THERAPY USING YIBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB FOR RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRiZ2012) M. Kanno | K. Miura | Y. Masaki | H. Tsujimura | M. Iino | J. Takizawa | Y. Maeda | K. Yamamoto | S. Tamura | A. Yoshida | H. Yagi | I. Yoshida | K. Kitazume | T. Masunari | I. Choi | Y. Kakinoki | R. Suzuki | T. Yoshino | S. Nakamura | T. Yoshida Oncology Center, Nara Medical University Hospital, Kashihara, Japan; Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan; Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan; Division of Medical Oncology, Chiba Cancer Center, Chiba, Japan; Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan; Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Department of Hematology, Okayama City Hospital, Okayama, Japan; Department of Hematology/Oncology, Kinan Hospital, Tanabe, Japan; Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan; Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan; Department of Hematologic Oncology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan; Department of Hematology, Showa General Hospital, Kodaira, Japan; Department of Infectious Diseases, Chugoku Central Hospital, Fukuyama, Japan; Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan; Department of Hematology, Asahikawa City Hospital, Ashikawa, Japan; Department of Oncology/Hematology, Innovative Cancer Center, Shimane University Hospital, Izumo, Japan; Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Department of Pathology and Biological Response, Nagoya University Graduate School of Medicine, Nagoya, Japan; Member, Society of Lymphoma Treatment in Japan (SoLT-J), Kanazawa, Japan